Cgmp manufacturing of glycopeptide immunogen nanoparticle vaccine
Ended Awarded Last action
- Contract number
- 75N93019F00132
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,683,305
Award facts
- Opportunity
-
- NIHAI2015035 Solicitation number
- Contract value 100% obligated
- $4,683,305.11 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$939,118 | |
| Other Administrative Action | $0 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $523,084 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Definitize Change Order | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $1,949,201 | |
| Original award | $3,150,138 |
Show all 11
About this award
This federal contract award to Advanced Bioscience Laboratories, Inc. (ABL) is for the cGMP manufacturing of a glycopeptide immunogen nanoparticle vaccine in support of preclinical development activities for the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The $4,683,305.11 cost-plus-fixed-fee contract has a period of performance through December 31, 2025. ABL, a for-profit manufacturer of goods, will provide a range of services including biologics manufacturing, testing, storage, and quality assurance to support this NIAID preclinical development program. The contract does not have a set-aside designation, reflecting ABL's status as a large business. ABL has been awarded multiple Indefinite Delivery Vehicles (IDVs) with federal health agencies such as NIAID, the National Cancer Institute, and the National Institute of Neurological Disorders and Stroke, demonstrating its broad capabilities in biopharmaceutical research and development.
Quick answers
Who was awarded contract 75N93019F00132?
75N93019F00132 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 16, 2019.
How much is contract 75N93019F00132 worth?
The government has obligated $4,683,305 on 75N93019F00132.
Is contract 75N93019F00132 an order under another contract?
Yes. 75N93019F00132 is a delivery order under HHSN272201700010I, an indefinite delivery contract.
Was contract 75N93019F00132 competed?
The extent of competition for 75N93019F00132 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award